Targeted polymeric therapeutic nanoparticles: Design and interactions with hepatocellular carcinoma

Biomaterials

Volumn 56, Issue , 2015, Pages 229-240

  Wang, Qi ^a,b   Sun, Ying ^a   Zhang, Zhirong ^b   Duan, Yourong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis pathway; Cell membrane potential; Liver tumors; Polymeric therapeutic nanoparticles

Indexed keywords

CELL DEATH; FUNCTIONAL POLYMERS; MITOCHONDRIA; NANOPARTICLES; TUMORS;

APOPTOSIS PATHWAYS; CLINICAL APPLICATION; DRUG DELIVERY SYSTEM; ENDOPLASMIC RETICULUM; HEPATOCELLULAR CARCINOMA; LIVER TUMORS; MEMBRANE POTENTIALS; MITOCHONDRIAL APOPTOSIS;

TARGETED DRUG DELIVERY;

CALCIUM PHOSPHATE; CHITOSAN; COPOLYMER; MACROGOL; MITOXANTRONE; NANOCARRIER; PHOSPHATIDYLSERINE; POLYGLACTIN; POLYLACTIDE; POLYLYSINE; POTASSIUM ION; MACROGOL DERIVATIVE; NANOPARTICLE; POLYMER; POTASSIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELLULAR DISTRIBUTION; CIRCULATION TIME; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; IN VIVO STUDY; LIVER; LIVER CELL CARCINOMA; LUNG; LYSOSOME; MALE; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POTASSIUM CURRENT; POTASSIUM TRANSPORT; PRIORITY JOURNAL; SURFACE CHARGE; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE; CHEMISTRY; DRUG DESIGN; HUMAN; LIVER NEOPLASMS; MEMBRANE POTENTIAL; METABOLISM; NANOMEDICINE; PERMEABILITY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MEMBRANE; DRUG DESIGN; HUMANS; LIVER NEOPLASMS; LYSOSOMES; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOMEDICINE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PERMEABILITY; POLYETHYLENE GLYCOLS; POLYMERS; POSITRON-EMISSION TOMOGRAPHY; POTASSIUM; TISSUE DISTRIBUTION;

EID: 84928396757     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.03.050     Document Type: Article

References (54)

1. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
2. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971-3010.
3. Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S., Leszczyniecka M., et al. Validating cancer drug targets. Nature 2006, 441:451-456.
4. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
5. Liu P., Yu H., Sun Y., Zhu M., Duan Y. AmPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 2012, 33:4403-4412.
6. Liu P., Qin L., Wang Q., Sun Y., Zhu M., Shen M., et al. cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials 2012, 33:6739-6747.
7. Wang Y., Liu P., Qiu L., Sun Y., Zhu M., Gu L., et al. Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials 2013, 34:4068-4077.
8. Wang Y., Liu P., Duan Y., Yin X., Wang Q., Liu X., et al. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. Biomaterials 2014, 35:983-992.
9. Vader P., Crielaard B.J., van Dommelen S.M., van der Meel R., Storm G., Schiffelers R.M. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. JControl Release 2012, 160:211-216.
10. Wang K.W., Zhou L.Z., Sun Y., Wu G.J., Gu H.C., Duan Y.R., et al. Calcium phosphate/PLGA-mPEG hybrid porous nanospheres: a promising vector with ultrahigh gene loading and transfection efficiency. JMater Chem 2010, 20:1161-1166.
11. Wu J., Zhu Y.J., Chen F., Zhao X.Y., Zhao J., Qi C. Amorphous calcium silicate hydrate/block copolymer hybrid nanoparticles: synthesis and application as drug carriers. Dalton Trans 2013, 42:7032-7040.
12. Wang K.W. Calcium phosphate/block copolymer hybrid porous nanospheres: preparation and application in drug delivery. Mater Lett 2010, 64:2299-2301.
13. Wang Q., Liu P., Liu P., Gong T., Li S., Duan Y., et al. Preparation, blood coagulation and cell compatibility evaluation of chitosan-graft-polylactide copolymers. Biomed Mater 2014, 9:15007.
14. Li S. Crystalline oligomeric stereocomplex as an intermediate compound in racemic poly( DL-lactic acid) degradation. Polym Int 1994, 33:37-41.
15. Hu Y. Novel bioresorbable hydrogels prepared from chitosan- graft-polylactide copolymers. Soc Chem Ind 2012, 61:74-81.
16. Gercel-Taylor C., Atay S., Tullis R.H., Kesimer M., Taylor D.D. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem 2012, 428:44-53.
17. Anderson W., Kozak D., Coleman V.A., Jamting A.K., Trau M. Acomparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions. JColloid Interface Sci 2013, 405:322-330.
18. Pannicke T., Faude F., Reichenbach A., Reichelt W. Afunction of delayed rectifier potassium channels in glial cells: maintenance of an auxiliary membrane potential under pathological conditions. Brain Res 2000, 862:187-193.
19. Peixoto P.M., Ryu S.Y., Kinnally K.W. Mitochondrial ion channels as therapeutic targets. FEBS Lett 2010, 584:2142-2152.
20. Hughes S., El H.A., Dobson J. Magnetic micro- and nanoparticle mediated activation of mechanosensitive ion channels. Med Eng Phys 2005, 27:754-762.
21. Prevarskaya N., Skryma R., Shuba Y. Ion channels and the hallmarks of cancer. Trends Mol Med 2010, 16:107-121.
22. 2+ selectivity of a voltage-gated calcium channel. Nature 2014, 505:56-61.
23. Takeuchi A., Reyes N., Artigas P., Gadsby D.C. The ion pathway through the opened Na(+),K(+)-ATPase pump. Nature 2008, 456:413-416.
24. Szabo I., Bock J., Grassme H., Soddemann M., Wilker B., Lang F., et al. Mitochondrial potassium channel Kv1.3 mediates bax-induced apoptosis in lymphocytes. Proc Natl Acad Sci U S A 2008, 105:14861-14866.
25. Camacho J. Ether a go-go potassium channels and cancer. Cancer Lett 2006, 233:1-9.
26. Karki P., Seong C., Kim J.E., Hur K., Shin S.Y., Lee J.S., et al. Intracellular K(+) inhibits apoptosis by suppressing the Apaf-1 apoptosome formation and subsequent downstream pathways but not cytochrome c release. Cell Death Differ 2007, 14:2068-2075.
27. Daniel P.T., Koert U., Schuppan J. Apoptolidin: induction of apoptosis by a natural product. Angew Chem Int Ed Engl 2006, 45:872-893.
28. Reddy B.S., Banerjee R. 17Beta-estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells. Angew Chem Int Ed Engl 2005, 44:6723-6727.
29. Wang J., Fang X., Liang W. Pegylated phospholipid micelles induce endoplasmic reticulum-dependent apoptosis of cancer cells but not normal cells. ACS Nano 2012, 6:5018-5030.
30. 2+ entry, mitochondrial perturbation and caspase overactivation. Cell Death Dis 2012, 3. e434.
31. 2+ store to the plasma membrane. Nature 2005, 437:902-905.
32. Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005, 6:318-327.
33. Minton K. Phagocytosis: ER fails to make a contribution. Nat Rev Immunol 2005, 5. 902-902.
34. Cristofanon S., Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 2012, 3. e432.
35. Hughes A.L., Gottschling D.E. An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. Nature 2012, 492:261-265.
36. Boren J., Brindle K.M. Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ 2012, 19:1561-1570.
37. Joiner M.L., Koval O.M., Li J., He B.J., Allamargot C., Gao Z., et al. CaMKII determines mitochondrial stress responses in heart. Nature 2012, 491:269-273.
38. Vafai S.B., Mootha V.K. Mitochondrial disorders as windows into an ancient organelle. Nature 2012, 491:374-383.
39. Li N., Zhang C.X., Wang X.X., Zhang L., Ma X., Zhou J., et al. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials 2013, 34:3366-3380.
40. Anvekar R.A., Asciolla J.J., Lopez-Rivera E., Floros K.V., Izadmehr S., Elkholi R., et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 2012, 3. e420.
41. Wang D., Wang J., Bonamy G.M., Meeusen S., Brusch R.G., Turk C., et al. Asmall molecule promotes mitochondrial fusion in mammalian cells. Angew Chem Int Ed Engl 2012, 51:9302-9305.
42. Mahajan N.P., Linder K., Berry G., Gordon G.W., Heim R., Herman B. Bcl-2 and bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer. Nat Biotechnol 1998, 16:547-552.
43. Desai B.N., Krapivinsky G., Navarro B., Krapivinsky L., Carter B.C., Febvay S., et al. Cleavage of TRPM7 releases the kinase domain from the ion channel and regulates its participation in Fas-induced apoptosis. Dev Cell 2012, 22:1149-1162.
44. Petit A., Mwale F., Zukor D.J., Catelas I., Antoniou J., Huk O.L. Effect of cobalt and chromium ions on bcl-2, bax, caspase-3, and caspase-8 expression in human U937 macrophages. Biomaterials 2004, 25:2013-2018.
45. Werth J.L., Deshmukh M., Cocabo J., Johnson E.J., Rothman S.M. Reversible physiological alterations in sympathetic neurons deprived of NGF but protected from apoptosis by caspase inhibition or bax deletion. Exp Neurol 2000, 161:203-211.
46. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., et al. Aconserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001, 410:112-116.
47. Serrano M.C., Pagani R., Manzano M., Comas J.V., Portoles M.T. Mitochondrial membrane potential and reactive oxygen species content of endothelial and smooth muscle cells cultured on poly(epsilon-caprolactone) films. Biomaterials 2006, 27:4706-4714.
48. Ramzan R., Staniek K., Kadenbach B., Vogt S. Mitochondrial respiration and membrane potential are regulated by the allosteric ATP-inhibition of cytochrome c oxidase. Biochim Biophys Acta 2010, 1797:1672-1680.
49. Bensassi F., Gallerne C., Sharaf E.D.O., Hajlaoui M.R., Bacha H., Lemaire C. Cell death induced by the Alternaria mycotoxin Alternariol. Toxicol InVitro 2012, 26:915-923.
50. Huttemann M., Helling S., Sanderson T.H., Sinkler C., Samavati L., Mahapatra G., et al. Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome c oxidase and cytochrome c in ischemia/reperfusion injury and inflammation. Biochim Biophys Acta 2012, 1817:598-609.
51. Kreso A., van Galen P., Pedley N.M., Lima-Fernandes E., Frelin C., Davis T., et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014, 20:29-36.
52. Liao A.H., Wu S.Y., Wang H.E., Weng C.H., Wu M.F., Li P.C. Evaluation of 18F-labeled targeted perfluorocarbon-filled albumin microbubbles as a probe for microUS and microPET in tumor-bearing mice. Ultrasonics 2013, 53:320-327.
53. Mading P., Fuchtner F., Wust F. Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). Appl Radiat Isot 2005, 63:329-332.
54. Kapty J., Kniess T., Wuest F., Mercer J.R. Radiolabeling of phosphatidylserine-binding peptides with prosthetic groups N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide ([18F]FBAM) and N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). Appl Radiat Isot 2011, 69:1218-1225.